Kamada Ltd (KMDA): Price-to-Sales Ratio

Corporate company logo of Kamada Corp (KMDA)

Kamada Ltd. maintains its leadership in the production of plasma-derived therapies for the treatment of rare lung pathologies. The current revenue multiple on GURU.Markets contains data where 2.40 is the current value of the indicator. Business stability relies on government contracts and pipeline diversification, although dependence on raw materials and regulatory pressure create risks for profitability.

KMDA: Kamada Ltd. P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Kamada Corp (KMDA)

- share price and consensus valuation forecast:
Price Performance Chart kamada.com|KMDA - Price Target Chart
- stock exchange capitalization data:
Market Valuation Kamada Corp|KMDA - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Kamada|KMDA - Book Capitalization|Market Capitalization to Book Value Ratio kamada.com|KMDA - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Kamada Ltd.|KMDA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Kamada Pharma|KMDA - Company Aggregate Debts|Debts to Book Capitalization Kamada Corp|KMDA - Company Long-Term Debt|Company Short-Term Debts Kamada|Quick Ratio kamada.com
- earnings and valuation multiples information:
KMDA - Company Net Income|Future Profit Kamada Ltd.|KMDA - P/E Multiple|Forward P/E Multiple Kamada Ltd|KMDA - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Kamada Corp|KMDA - Operating profit EBITDA|Net earnings per share (EPS TTM) Kamada|KMDA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months kamada.com|KMDA - Earnings per share growth in current year|Net earnings per share growth forecast for next year Kamada Ltd.
- issuer revenue and sales details:
KMDA - Company Sales|Company Projected Revenue Volume kamada.com|KMDA - P/S Multiple|Market Cap to Projected Revenue Kamada Corp
General company analysis:KMDA kamada.com
Finished products of Kamada Ltd.

Investors are assessing the potential of Kamada Ltd. (KMDA) through the price-to-sales ratio, which determines the value of each dollar of revenue. By analyzing this P/S chart, one can identify asset overheating, given the stable demand for life-saving plasma-derived therapies that renders the business resilient to economic cycles and market volatility.

Competitors of Kamada Ltd.

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple fulcrumtx.com FULC|ABEO - Price-to-Revenue Ratio|MREO - P/S Multiple|PLX: P/S Multiple|Pliant Therapeutics, Inc. (PLRX) - P/S Multiple|Price-to-Revenue Ratio Applied Therapeutics|Market Cap to Revenue aileronrx.com (RNTX)|P/S Multiple GELS|P/S Multiple aytubio.com (AYTU)|P/S Multiple CMMB (Chemomab Therapeutics Ltd.)|SRXH: Market Cap to Revenue Ratio|Polyrizon Ltd. - P/S Multiple|AEZS - P/S Multiple|CYTH (Cyclo Therapeutics, Inc.) - Market Cap to Revenue|Inozyme Pharma - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Reneo Pharma|Price-to-Revenue Ratio CSCI